Connect with us

Cannabis News

Medical Marijuana Helps People Stop Using Opioids, Sleeping Aids And Other Prescription Drugs, Study Shows

Published

on

Using medical marijuana appears to help reduce the use of other medications, including opioids, sleep aids and antidepressants, according to a new study of more than 3,500 patients. They experience far fewer negative side effects after switching from prescription drugs to cannabis.

The survey results show that across all medication categories, patients were able to reduce their use of other prescription drugs by an average of 84.5 percent after starting to use medical cannabis.

More than half of the patients (58.9 percent) completely stopped using other prescription drugs.

The study, conducted and published by medical cannabis and telehealth company Bloomwell, conducted an online survey of 3,528 patients in Germany last month.

“Through the use of medical cannabis, patients were able to reduce their use of other prescription medications by an average of 84.5% across all categories.”

93.4 percent of patients taking sleeping pills were able to cut their use in half after starting medical marijuana, and 75.5 percent were able to get off the medication completely.

For methylphenidate, an ADHD drug sold under the name Ritalin, 77.3 percent of medical marijuana patients stopped completely.

61 percent of patients who were previously dependent on opioids were able to stop completely with the help of medical marijuana.

Stopping the use of prescription drugs led to a significant reduction in drug-related side effects, with 60.7 percent reporting no longer experiencing them.

“These patient reports demonstrate that in many cases, in addition to the treatment of the actual symptoms, one of the key reasons for an individual therapeutic trial with medical cannabis is the absence or reduction of medication-related side effects,” the study concluded.

“60.7% of patients reported no longer experiencing medication-related side effects from using medical cannabis.”

There were positive side effects, however, with 67.8 percent saying medical cannabis helped them concentrate better, 61.9 percent said it helped them foster more social relationships, and 53.9 percent experienced fewer sick days from work.

“The primary reason for prescribing medicinal cannabis, in addition to treating symptoms, is to reduce or avoid the side effects of other medications,” Julian Wichmann, Bloomwell’s founder and CEO, said in a press release. “For example, anyone who can completely stop opioids using medical cannabis has a good chance of going about their daily lives and working without side effects.”

“So we shouldn’t demand restrictions on access to medical cannabis, but rather make sure doctors are willing to do an individual therapeutic trial with medical cannabis, or at least recommend it and refer patients to their colleagues,” he said. “At the same time, our survey shows that we should finally discuss the great benefits of medical cannabis more openly, instead of only warning about the empirically unproven risks and discrediting the flower.”

This is not the first study to position medical cannabis as a safer alternative to opioids and other prescription drugs.

About One in three Americans who use CBD say they take it as an alternative or supplement to at least one medication—especially painful ones—according to a federally funded study published in February.

Also, a recent federally funded study, published by the American Medical Association (AMA), added further evidence Marijuana can be an effective substitute for opioids in the treatment of chronic pain.

Other studies published by the AMA have found legalizing marijuana for medical or recreational purposes “Significantly associated with reduced opioid use among patients diagnosed with cancer.”

A separate paper published in October also found that Legalizing medical marijuana “is associated with a significant reduction in opioid prescriptions.”

In August, however, Australian researchers published a study that shows this Marijuana can be an effective substitute for opioids in pain management treatment.

Another study published last year in the journal Drug and Alcohol Review found that daily drug users with chronic pain cannabis use was associated with greater likelihood of opioid cessation-Especially among men.

Other studies also found this legalizing medical cannabis appears to have significantly reduced payments to doctors from opioid manufacturers who specialize in pain, the authors found that “this reduction is a consequence of the availability of medical marijuana as a substitute” for prescription analgesics.

Other recent studies also showed a decline in fatal opioid overdoses in jurisdictions where marijuana was legalized for adults. That research found a ‘consistent negative relationship’ between legalization and fatal overdoses, effects more pronounced in states that legalized cannabis earlier in the opioid crisis. The authors estimated that legalizing recreational marijuana “is associated with a decrease of 3.5 deaths per 100,000 people.”

“Our findings suggest that expanding access to recreational marijuana could help combat the opioid epidemic,” the report said. “Prior studies overwhelmingly indicate that marijuana (especially for medical use) can reduce opioid prescriptions, and we see it successfully reducing overdose deaths as well.”

Another recently published report on prescription opioid use in Utah follows the state legalizing medical marijuana found that the availability of legal cannabis reduced opioid use among chronic pain patients and helped reduce prescription drug overdose deaths across the state. Overall, the study’s results indicated that “cannabis plays a significant role in pain management and reducing opioid use,” he said.

President Donald Trump said in December that marijuana can “make people feel a lot better.” and serves as a “substitute for addictive and potentially deadly opioid painkillers.” issued an executive order to federally regulate cannabis and promote access to CBD for therapeutic purposes. He clarified, however, that he personally has no interest in using marijuana himself.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Become a patron on Patreon!

Cannabis News

Maximizing cannabis yields with intercanopy and subcanopy lighting

Published

on

By







Continue Reading

Cannabis News

Transportation Groups Warn Feds Of Marijuana Rescheduling’s ‘Consequences’ For Drug Testing Of Truck Drivers And Pilots

Published

on

By

A coalition of transportation and safety organizations said they have “serious safety concerns” about the Trump administration’s move to federally regulate marijuana.

Led by the American Trucking Association, the groups sent a letter to federal officials Monday asking them to take steps to ensure truck drivers, pilots, transit operators and other safety-sensitive workers continue to be tested for cannabis.

“If employers do not take the necessary steps to preserve the ability of security-sensitive transportation workers to test for marijuana, this change could have significant consequences for the safety of passengers and the entire transportation industry,” wrote Acting Attorney General Todd Blanche, Drug Enforcement Administration (DEA) Administrator Terrance Cole, Health and Human Services Secretary Robert F. Kennedy, and Transportation Secretary J.

The organizations said they understand that federal officials are being “urgently” reorganized under an executive order from President Donald Trump, that they are “deeply concerned that the current process does not adequately take into account agencies responsible for transportation safety or protecting the traveling public” and that they want the agencies to “work together.” ongoing cannabis redistricting hearings and rulemaking process to address these concerns.

In May, the Department of Transportation (DOT) issued new guidelines saying just that Truck drivers, airline pilots and other safety-sensitive workers still cannot use medical marijuana without penalty despite the Trump administration’s move to reschedule.

“Marijuana use is incompatible with safety-sensitive functions,” the department said.

Medical review officers (MROs) who receive drug test results indicating cannabis use cannot rule them out as negative for illegal substance use, even if an employee claims it was a result of state-licensed medical marijuana.

“Currently, there is no way for an MRO to verify that a laboratory-confirmed marijuana drug test result is positive when an employee claims the positive was caused by a state-licensed marijuana product,” the DOT said, explaining that after the reprogramming, medical marijuana dispensed under state law “does not” constitute a drug approved by the Food and Drug Administration (FDA).

The transportation groups said in the new letter that the DOT’s drug-testing program “is in accordance with the Department of Health and Human Services’ (HHS) Mandatory Guidelines for Federal Workplace Drug Testing Programs and HHS-certified laboratories.”

“While DOT has expressed its intention to continue testing marijuana, a commitment we greatly appreciate, it is unclear whether DOT will retain its ability to rely on HHS procedures and certifications after the rescheduling,” they wrote. “Without this alignment, DOT may retain the authority to conduct testing, but lack the scientific and procedural infrastructure to do so.”

“Practically, this would mean that truck and bus drivers, pilots, flight attendants, air traffic controllers, air mechanics, railroad workers, dispatchers and signal workers, transit operators and pipeline workers could continue to perform high-risk safety roles without a reliable means of verifying that they are not actively using marijuana. It relies on controlled substance testing to identify end use and prevent potentially impaired individuals from fulfilling their safety-related obligations. While the planning could create legal or regulatory loopholes, the regulated employer-based drug testing agency warned that the final rules should not jeopardize marijuana testing for safety-sensitive transportation workers.”

“Regardless of the broader policy goals of the review, the federal government should not move forward to preserve transportation drug testing programs and mitigate the risks of increased and unchecked deterioration of our roads, railroads, public transportation systems, pipelines, airspace, and maritime corridors,” the letter says.

The organizations specifically ask federal officials to:

  • Support long-term marijuana testing for all safety-sensitive transportation workers;
  • Confirm the authority of DOT-regulated employers to perform such tests;
  • Ensure HHS laboratory certification and testing guidelines remain available and aligned with DOT’s safety mission; and
  • Establish a coordinated federal strategy to address the transportation security implications of rescheduling.

“The public and the workers who keep our transportation system running safely deserve a process that ensures these safeguards are firmly in place before any final action is taken,” he said. the letter he says

Earlier this month, the House Appropriations Committee approved a provision to allow federal officials to continue requiring government employees and security-sensitive employees, such as truck drivers and airline pilots must be drug tested for marijuana, “regardless of any future change in legal status or schedule.”

This was followed by a press conference organized by prohibitionist groups and a drug-testing industry association, where both Republican lawmakers joined the proclamation. “Cut” to marijuana rescheduling by asserting that safety-sensitive transportation workers can still be punished for testing positive for THC.

Legislators and abolitionist activists argued that moving marijuana to Schedule III would lead to a 1986 executive order signed by President Ronald Reagan defining illegal drugs under the Controlled Substances Act (CSA) in relation to the use of cannabis by truck drivers and other airline employees.

Last October, Transportation Secretary Sean Duffy suggested that President Donald Trump was “putting pressure” on rescheduling cannabis.arguing that marijuana is “truly addictive” and that policy reform on the issue sends a “dangerous” message.

“At a time when the culture is encouraging and celebrating the use of marijuana, we’re not talking about risk,” Duffy said.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

Experts say THC percentage is the wrong way to shop for cannabis

Published

on

By


Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media